ARNA, Arena Pharmaceuticals, Inc.

** ARNA and Eisai Inc. reported that the FDA has accepted for filing and review ARNA's resubmission of the New Drug Application for lorcaserin.

According to the company, the FDA considers the resubmission a complete, class 2 response, and assigned a new Prescription Drug User Fee Act (PDUFA) target date of June 27, 2012.